Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10964196 | Vaccine | 2015 | 8 Pages |
Abstract
From both the perspectives, the introduction of rotavirus vaccine to the Albanian immunization schedule is either cost-effective or highly cost-effective for a range of plausible scenarios. In most scenarios, including the base-case scenario, the discounted cost per DALY averted was less than three times the gross domestic product (GDP) per capita. However, rotavirus vaccination was not cost-effective when rotavirus cases and deaths were based on plausible minimum estimates. Introduction of RV1 would yield similar benefits at lower cost.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Albana Ahmeti, Iria Preza, Artan Simaku, Erida Nelaj, Andrew David Clark, Ana Gabriela Felix Garcia, Carlos Lara, Céline Hoestlandt, Julia Blau, Silvia Bino,